OTLK
Price:
$5.23
Market Cap:
$123.72M
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, In...[Read more]
Industry
Biotechnology
IPO Date
2016-06-14
Stock Exchange
NASDAQ
Ticker
OTLK
According to Outlook Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.89. This represents a change of 29.38% compared to the average of -0.69 of the last 4 quarters.
The mean historical PE Ratio of Outlook Therapeutics, Inc. over the last ten years is -2.44. The current -0.89 PE Ratio has changed 3.54% with respect to the historical average. Over the past ten years (40 quarters), OTLK's PE Ratio was at its highest in in the June 2024 quarter at 0.97. The PE Ratio was at its lowest in in the March 2023 quarter at -10.51.
Average
-2.44
Median
-1.43
Minimum
-6.23
Maximum
-0.79
Discovering the peaks and valleys of Outlook Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 320.38%
Maximum Annual PE Ratio = -0.79
Minimum Annual Increase = -76.07%
Minimum Annual PE Ratio = -6.23
Year | PE Ratio | Change |
---|---|---|
2023 | -0.94 | -76.07% |
2022 | -3.92 | -37.14% |
2021 | -6.23 | 320.38% |
2020 | -1.48 | 88.81% |
2019 | -0.79 | -74.61% |
2018 | -3.09 | 265.09% |
2017 | -0.85 | -38.24% |
2016 | -1.37 | 1.29% |
2015 | -1.35 | -69.21% |
The current PE Ratio of Outlook Therapeutics, Inc. (OTLK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.70
5-year avg
-2.67
10-year avg
-2.44
Outlook Therapeutics, Inc.’s PE Ratio is greater than Checkpoint Therapeutics, Inc. (-1.91), less than Mustang Bio, Inc. (-0.16), greater than Reviva Pharmaceuticals Holdings, Inc. (-1.31), less than Fortress Biotech, Inc. (-0.66), less than Kodiak Sciences Inc. (-0.71), greater than Ocuphire Pharma, Inc. (-2.42), greater than Protalix BioTherapeutics, Inc. (-5.39), greater than EyePoint Pharmaceuticals, Inc. (-5.29), greater than SELLAS Life Sciences Group, Inc. (-2.11), less than Eyenovia, Inc. (-0.69), less than Cidara Therapeutics, Inc. (-0.44), less than Fortress Biotech, Inc. (-0.66), greater than Selecta Biosciences, Inc. (-3.39), less than X4 Pharmaceuticals, Inc. (7.06), greater than Inozyme Pharma, Inc. (-3.62), greater than Terns Pharmaceuticals, Inc. (-6.42), greater than Day One Biopharmaceuticals, Inc. (-7.33), greater than HOOKIPA Pharma Inc. (-1.04), greater than Heron Therapeutics, Inc. (-6.71), less than Galera Therapeutics, Inc. (-0.14),
Company | PE Ratio | Market cap |
---|---|---|
-1.91 | $98.39M | |
-0.16 | $7.95M | |
-1.31 | $41.37M | |
-0.66 | $42.87M | |
-0.71 | $139.96M | |
-2.42 | $34.58M | |
-5.39 | $79.43M | |
-5.29 | $461.86M | |
-2.11 | $81.06M | |
-0.69 | $41.29M | |
-0.44 | $76.72M | |
-0.66 | $44.93M | |
-3.39 | $135.20M | |
7.06 | $104.67M | |
-3.62 | $324.34M | |
-6.42 | $698.29M | |
-7.33 | $1.24B | |
-1.04 | $136.28M | |
-6.71 | $321.54M | |
-0.14 | $4.13M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Outlook Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Outlook Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Outlook Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Outlook Therapeutics, Inc. (OTLK)?
What is the highest PE Ratio for Outlook Therapeutics, Inc. (OTLK)?
What is the 3-year average PE Ratio for Outlook Therapeutics, Inc. (OTLK)?
What is the 5-year average PE Ratio for Outlook Therapeutics, Inc. (OTLK)?
How does the current PE Ratio for Outlook Therapeutics, Inc. (OTLK) compare to its historical average?